AI Science Tracker

Huashan Hospital, Fudan University

1 discovery from 2025

Discoveries

Machine learning identifies serum protein signatures for progression from asymptomatic atherosclerosis to ischemic stroke

In a discovery cohort of 43 patients with asymptomatic large-artery atherosclerosis and a validation cohort of 39, investigators combined serum proteomics with machine learning to distinguish acute ischemic stroke from large-artery atherosclerosis. XGBoost selected a three-protein panel (RNASE4, HBA1 and ATF6B; reported AUC 0.917, specificity 80%) and a six-protein panel distinguishing patients from healthy controls (reported AUC 0.971, specificity 86%). ELISA assays confirmed higher GUCA2A and FLNA in patient groups.

Technology: XGBoost machine-learning models applied to serum proteomics; DeepPRM-Stellar targeted mass spectrometry supported peptide validation and panel optimization

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: In a discovery cohort of 43 patients with asymptomatic large-artery atherosclerosis and a validation cohort of 39, investigators combined serum proteomics with machine learning to distinguish acute ischemic stroke from large-artery atherosclerosis.
  • Still unknown: The abstract reports 43 discovery and 39 validation participants, but does not establish prospective prediction or external clinical deployment. The signatures are candidate biomarkers, not a validated clinical test. Reported performance comes from this study and should not be interpreted as patient benefit or causal evidence. ELISA confirmation is reported for GUCA2A and FLNA, not every protein in the ML panels.
  • AI role: The study reports that machine-learning techniques were used to identify circulating biomarkers of progression and that XGBoost selected the three- and six-protein signatures from targeted proteomic measurements. ELISA follow-up confirmed GUCA2A and FLNA group differences. The models are retrospective cohort analyses; the study did not prospectively predict future stroke events.

Evidence sources: https://pubmed.ncbi.nlm.nih.gov/40692393/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 42 of works of the same type, year and subfield (OpenAlex work metrics, 2 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.